Skip to main content

Table 1 Baseline characteristics of patients

From: Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort

 

SOF SMV 12 weeks n = 485

SOF SMV 24 weeks n = 51

SOF SMV RBV 12 weeks n = 45

SOF SMV RBV 24 weeks n = 18

p value

Age (years), mean ± SD

61 ± 11

60 ± 10

59 ± 11

58 ± 13

0.2908

Gender Male n (%)

256 (53)

24 (47)

28 (62)

14 (78)

0.0866

BMI (kg/m2) n (%)

  ≥ 30

74 (15)

10 (20)

7 (16)

2 (11)

0.9531

  < 18.5

12 (2)

2 (4)

0 (0)

0 (0)

 [25–30[

163 (34)

14 (27)

17 (38)

7 (39)

 [18.5–25[

233 (48)

25 (49)

21 (47)

9 (50)

Chronic hepatitis duration (years), mean ± SD

16 ± 8

15 ± 7

16 ± 9

11 ± 8

0.0814

HCV genotype n (%)

 1a

110 (23)

11 (22)

14 (31)

6 (33)

0.2543

 4

99 (20)

17 (33)

10 (22)

6 (33)

 1 not subtyped

25 (5)

1 (2)

3 (7)

0 (0)

 1b

251 (52)

22 (43)

18 (40)

6 (33)

Diabetes n (%)

104 (21)

7 (14)

9 (20)

1 (6)

0.2710

Hypertension n (%)

194 (40)

25 (49)

18 (40)

4 (22)

0.2571

Cirrhosis n (%)

259 (54)

33 (65)

27 (60)

16 (89)

0.0117

 •Child-Pugh score B or C

17 (7)

8 (24)

1 (4)

2 (13)

0.0083

 •MELD ≥15

19 (8)

4 (13)

1 (4)

3 (19)

0.2444

 •Elastography ≥14.5 kPa

131 (51)

15 (45)

14 (52)

10 (63)

0.7540

 •Fibrotest ≥0.73

70 (27)

10 (30)

11 (41)

10 (63)

0.0175

 •Liver biopsy > 2 years

148 (57)

20 (61)

14 (52)

7 (44)

0.6618

 •Liver biopsy < 2 years

18 (7)

2 (6)

1 (4)

0 (0)

0.9306

Decompensated cirrhosis n (%)

16 (3)

6 (12)

2 (4)

0 (0)

0.0483

 •Child-Pugh score B or C

6 (38)

4 (67)

1 (50)

 

0.5589

 •MELD score, mean ± SD

9.7 ± 2.9

12.3 ± 3.9

12.5 ± 0.7

 

0.1793

Albumin (< 30 g/L) n (%)

12 (3)

5 (11)

1 (3)

1 (6)

0.0415

Prothrombin time (≤70%) n (%)

45 (10)

11 (22)

6 (14)

6 (33)

0.0037

AST (> 5 x ULN) n (%)

28 (6)

4 (8)

3 (7)

2 (12)

0.4951

ALT (> 5 x ULN) n (%)

31 (6)

2 (4)

1 (2)

1 (6)

0.7735

Haemoglobin (≤12 g/dL in women or ≤ 13 g/dL in men) n (%)

58 (12)

8 (16)

5 (11)

1 (6)

0.7365

Platelets < 100,000/mm3

87 (19)

15 (30)

11 (25)

8 (47)

0.0109

Bilirubin conj ≥5 μmol/L

133 (52)

20 (63)

16 (57)

13 (100)

0.0021

Treatment history n (%)

 •Naïve patients

141 (29)

13 (25)

14 (31)

5 (28)

0.0618

 •Experienced patients, last treatment PEG/RBV

324 (67)

35 (69)

25 (56)

10 (56)

 •Experienced patients, last treatment 1rst generation PI/PEG/RBV

20 (4)

3 (6)

6 (13)

3 (17)

Response profile in treatment experienced patients

 •Unknown

164 (48)

20 (53)

17 (55)

6 (46)

0.8370

 •Responders

86 (25)

9 (24)

4 (13)

3 (23)

 •Not responders

94 (27)

9 (24)

10 (32)

4 (31)

  1. SOF Sofosbuvir, SMV Simeprevir, RBV Ribavirine, PI Protease inhibitor, SD Standard deviation, BMI Body mass index
  2. P value inferior to 0.05 are in boldface